कंपनी का अवलोकन
Sanara MedTech Inc. is a medical technology entity dedicated to the development, marketing, and distribution of surgical solutions for physicians, hospitals, clinics, and post-acute care settings across the United States. The corporation operates within the Healthcare sector, specifically functioning in the Medical Instruments & Supplies industry, which implies a focus on providing essential tools and consumables for clinical procedures. The company's operational scale is defined by a market capitalization of $155.84M, annual revenue of $103.12M, and an employee base of 108 individuals. These valuation and revenue figures indicate that Sanara MedTech is a mid-sized enterprise with a significant presence in the specialized medical supply chain, positioning it as a notable player relative to its specific niche market.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $103.12M, while the net income stood at -$387,683, and EBITDA was recorded at $11.81M. The substantial gap between the positive EBITDA of $11.81M and the negative net income of -$387,683 reveals a significant cost structure burden, likely driven by high interest expenses or non-operating costs associated with the company's debt load. Despite the negative net income, the generation of $8.54M in free cash flow demonstrates strong financial flexibility, indicating that the company can fund operations and potential capital expenditures without relying on external financing. The gross margin is an impressive 92.7%, suggesting high pricing power or low cost of goods sold, whereas the operating margin of 10.5% indicates healthy operational efficiency before interest and taxes. However, the profit margin of -36.4% reflects the impact of financing costs on the bottom line. In terms of balance sheet leverage, the company holds $16.58M in cash against $48.19M in debt, resulting in a debt-to-equity ratio of 812.73, which characterizes a highly leveraged financial position. The current ratio of 1.80 suggests adequate short-term liquidity, as current assets are significantly higher than current liabilities, providing a buffer against immediate obligations. Return on Equity is -1.8%, indicating that the company is currently diluting shareholder value through losses, while Return on Assets stands at 7.1%, showing that assets are generating positive earnings before financing effects.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is reported as -14.53, implying that the market prices future earnings expectations with a negative denominator or relies on alternative metrics for valuation. The price-to-book ratio is 25.60, indicating a substantial market premium over the company's tangible book value, which often occurs in growth-oriented sectors or companies with significant intangible assets. The price-to-sales ratio of 1.51 and the EV/EBITDA of 15.88 provide alternative valuation perspectives that suggest the stock is priced at a premium relative to its sales and earnings generation capabilities. The 52-week high is $35.95 and the 52-week low is $16.05, and the current trading price sits at a level that requires calculation relative to this range to determine its position within the annual volatility band. The beta value of 1.10 indicates that the stock's price volatility is slightly higher than the broader market, suggesting a higher sensitivity to market fluctuations compared to the overall index.
Growth & Income
The company achieved a revenue growth of 4.7% year-over-year, while earnings growth is listed as N/A due to the current period's net loss. Since earnings are negative, the growth trajectory for profitability cannot be calculated directly, but the revenue expansion suggests top-line momentum that management is attempting to translate into future earnings. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically reinvested into the business or retained to service debt rather than distributed to shareholders. This reinvestment strategy is consistent with the company's focus on funding growth initiatives and potentially reducing its significant debt load in the coming fiscal periods. The overall growth and income profile for Sanara MedTech Inc. is characterized by steady revenue expansion and a complete absence of dividend distributions, focusing entirely on capital preservation and operational scaling.